"Drs. James Hansen and Jiangbing Zhou of the Yale School of Medicine have confirmed that as a single agent PAT-DX1 localizes into xenograft triple negative breast cancer (TNBC) tumors in mice. Mice with TNBC tumors were treated with systemic administration of PAT-DX1, and at varying time points afterwards tumors were excised and examined for the presence of PAT-DX1. Preliminary pharmacokinetic analysis indicates that PAT-DX1 exhibited significant tumor penetration 8 hours after administration."
Seems price sensitive to me? @gassed
Ann: Preliminary PAT-DX1 pharmacokinetics, page-3
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
